📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: IDRx

1.1 - Company Overview

IDRx Logo

IDRx

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of oncology-based precision therapies for gastrointestinal stromal tumors (GIST). The clinical-stage biopharma designs precision combination medicines with engineered drug combinations to stop key tumor escape mechanisms and prolong response. Pipeline includes IDRX-42, a Phase 1 small-molecule tyrosine kinase inhibitor targeting genetic drivers and resistance mutations in GIST, and IDRX-73 targeting a key drug resistance mutation.

Products and services

  • Precision Combination Therapies: Architects medicines using engineered drug combinations to stop key tumor escape mechanisms and prolong response to therapy in gastrointestinal stromal tumors
  • IDRX-42: Produces a small-molecule tyrosine kinase inhibitor in Phase 1 study for GIST, targeting genetic drivers and resistance mutations
  • IDRX-73: Develops a mutation-selective therapy under development to selectively target a key drug resistance mutation in GIST.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to IDRx

Iambic Therapeutics Logo

Iambic Therapeutics

HQ: United States Website
  • Description: Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Iambic Therapeutics company profile →
ImClone Systems Logo

ImClone Systems

HQ: United States Website
  • Description: Provider of targeted biologic treatments and therapeutic antibodies for oncology, developing a portfolio to address the medical needs of patients with a variety of cancers.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ImClone Systems company profile →
Gilupi Logo

Gilupi

HQ: Germany Website
  • Description: Provider of medical devices and diagnostic solutions for in vivo isolation and analysis of rare circulating cells from blood. Offers GILUPI CellCollector for enriching circulating tumor cells, liquid biopsy sampling, immunofluorescence microscopy, NuPLex technology for RNA detection, and next-generation sequencing for genetic analysis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Gilupi company profile →
RedPath Integrated Pathology Logo

RedPath Integrated Pathology

HQ: United States Website
  • Description: Provider of reference laboratory services and oncology case support, offering PathFinderTG, a testing platform for resolving diagnoses from the original pathology specimen, serving pathologists, clinicians, and patients.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full RedPath Integrated Pathology company profile →
EOS Logo

EOS

HQ: Italy Website
  • Description: Provider of biopharmaceutical research and development focused on creating novel medicines for the treatment of cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full EOS company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for IDRx

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to IDRx

2.2 - Growth funds investing in similar companies to IDRx

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for IDRx

4.2 - Public trading comparable groups for IDRx

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to IDRx

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About IDRx

What does IDRx do?

IDRx is a provider of oncology-based precision therapies for gastrointestinal stromal tumors (GIST). The clinical-stage biopharma designs precision combination medicines with engineered drug combinations to stop key tumor escape mechanisms and prolong response. Pipeline includes IDRX-42, a Phase 1 small-molecule tyrosine kinase inhibitor targeting genetic drivers and resistance mutations in GIST, and IDRX-73 targeting a key drug resistance mutation.

Who are IDRx's competitors?

IDRx's competitors and similar companies include Iambic Therapeutics, ImClone Systems, Gilupi, RedPath Integrated Pathology, and EOS.

Where is IDRx headquartered?

IDRx is headquartered in United States.

How many employees does IDRx have?

IDRx has 1,000 employees 🔒.

When was IDRx founded?

IDRx was founded in 2010 🔒.

What sector and industry vertical is IDRx in?

IDRx is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for IDRx

Who are the top strategic acquirers in IDRx's sector and industry

Top strategic M&A buyers and acquirers in IDRx's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for IDRx?

Top strategic M&A buyers groups and sectors for IDRx include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in IDRx's sector and industry vertical

Which are the top PE firms investing in IDRx's sector and industry vertical?

Top PE firms investing in IDRx's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in IDRx's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in IDRx's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in IDRx's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to IDRx include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in IDRx's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for IDRx?

The key public trading comparables and valuation benchmarks for IDRx include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for IDRx for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for IDRx with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in IDRx's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for IDRx with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in IDRx's' sector and industry vertical?

Access recent funding rounds and capital raises in IDRx's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for IDRx